Table 4.
Stroke scores and laboratory findings according to short-term disability status in female patients with ischemic stroke.
| Independent (n = 354) (mRS = 0–2) | Dependent (n = 243) (mRS = 3–5) | p-value | |
|---|---|---|---|
| NIHSS | 3.01 ± 2.96 (0–22) | 10.77 ± 5.05 (2–25) | 0.001*a |
| GCS | 14.90 ± 0.41 (8–15) | 11.72 ± 1.82 (5–15) | 0.001*a |
| SEDAN score | 1.50 ± 1.10 (0–6) | 2.26 ± 1.08 (0–5) | 0.001*a |
| THRIVE score | 2.22 ± 1.32 (0–5) | 3.60 ± 1.75 (0–8) | 0.001* |
| mRS | 1.62± 1.15 (0–5) | 4.24 ± 0.74 (3–5) | 0.001*a |
| Blood Glucose (mg/dL) | 149.86 ± 76.26 (73–558) | 156.85 ± 74.04 (71–534) | 0.016* |
| Creatinine (mg/dL) | 0.89 ± 0.60 (0.37–6.26) | 0.88 ± 0.56 (0.34–5.55) | 0.828a |
| Hemoglobin (g/dL) | 12.66 ± 1.61 (4.6–16.3) | 12.66 ± 1.88 (7.50–21.9) | 0.793a |
| Leukocyte (K/uL) | 8.71 ± 5.95 (1.4–107.8) | 9.44 ± 3.43 (3.4–26.8) | 0.001*a |
| Urea (K/uL) | 41.84 ± 21.42 (13–221) | 47.46 ± 25.64 (11–228) | 0.001*a |
| Albumin (g/dL) | 3.57 ± 0.39 (2.3–4.3) | 3.30 ± 0.53 (1.8–4.4) | 0.001*a |
| C-reactive protein (mg/dL) | 31.61 ± 58.72 (0.3–476) | 48.99 ± 71.40 (1.11–471) | 0.002*a |
| LDL-cholesterol (mg/dL) | 124.75 ± 42.90 (49–301) | 129.30 ± 37.64 (37–249) | 0.080 |
| HDL-cholesterol (mg/dL) | 43.17 ± 10.11 (24–96) | 41.94 ± 11.33 (17–73) | 0.196a |
| Triglyceride (mg/dL) | 167.35 ± 98.08 (48–627) | 158.14 ± 84.42 (49–459) | 0.082a |
| Treatment (n, %) | |||
| IV thrombolysis | 16 (4.5) | 15 (6.2) | 0.016*b |
| Endovascular thrombectomy | 4 (1.1) | 21 (8.6) | |
| IV thrombolysis and thrombectomy | 8 (2.3) | 20 (8.2) |
NIHSS, NIH stroke score; GCS, Glasgow coma score; mRS, Modified Rankin score; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; n, Number; IV, Intravenous.
*Statistical significance value.
aIndependent Sample T test.
bChi-square (χ2) test.
Data are shown as mean ± SD (minimum–maximum unless otherwise indicated).